SAB BIOTHERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
SAB BIOTHERAPEUTICS, INC. (SABS) reported Payments to Acquire Debt Securities, Available-for-sale of $152.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $13.01M, a 24877.87% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $139.26M, a 196307.56% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $12.04M, a 820.27% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $129.87M, a 2604.28% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $142.04M, a 279.31% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $37.45M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $152.28M 10-Q · filed 2026-08-06 | $164.32M derived: sum of 3 quarters · filed 2026-08-06 | $294.19M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $139.26M 10-Q · filed 2026-05-12 | $151.31M derived: sum of 2 quarters · filed 2026-05-12 | $281.18M derived: sum of 3 quarters · filed 2026-05-12 | $281.23M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $141.91M derived: sum of 2 quarters · filed 2026-03-09 | $141.96M derived: sum of 3 quarters · filed 2026-08-06 | $142.04M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $129.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $129.92M derived: sum of 2 quarters · filed 2026-08-06 | $129.99M 10-Q · filed 2025-11-14 | $131.30M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $52.09K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $123.00K 10-Q · filed 2026-08-06 | $122.92K 10-Q · filed 2025-08-07 | $1.43M derived: sum of 3 quarters · filed 2026-08-06 | $6.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $70.91K 10-Q · filed 2026-05-12 | $1.38M derived: sum of 2 quarters · filed 2026-05-12 | $6.18M derived: sum of 3 quarters · filed 2026-05-12 | $6.29M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $6.11M derived: sum of 2 quarters · filed 2026-03-09 | $6.22M derived: sum of 3 quarters · filed 2026-03-09 | $37.45M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.91M derived: sum of 2 quarters · filed 2025-11-14 | $36.14M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $105.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $31.34M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $31.23M 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |